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Long-Term Nifedipine Unloading Therapy in Asymptomatic Patients
With Chronic Severe Aortic Regurgitation
ROLDANO SCOGNAMIGLIO, MD, GIUSEPPE FASOLI, MD, ANDREA PONCHIA, MD,
SERGIO DALLA-VOLTA, MD
Pad... Italy
Vasoditating agents acutely reduce regurgitant volume and
improve kit ventricular performaau in aortic regurgita-
tion, but more information is necessary about their long .
term efficacy. To evaluate the effects of 12 months of
therapy with nifdipine, a randomized, doubk-blnd, pla.
eebo-cootrolkd trial seas performed in 72 asymptoreadc
patients with severe aorta regurgitation.
At 12 months, patients receiving aifedipine had a signif
.
kant reduction In lent ventricular end-diasto8c volume
index (110 ± 19 versus 136 ± 22 mUm2, p < 0,01) and mass
(115 ± 19 versus 142 ± 16 g/m a, p < 0 .01) measured by
The role of early aortic valve replacement is an unanswered
question in asymptomatic patients with chronic severe aortic
regurgitation (1-3). Moreover, the ability of pharmacologic
treatment to prevent or delay myocardial dysfunction re-
mains a fundamental unsolved clinical problem . An absorb-
ing possibility is that the early administration of a vasodilator
drug during the long-standing asymptomatic phase of volume
overload without myocardial deterioration might be able to
reduce either the extent of left ventricular dilation or its
progression . Acute vasodilator administration reduces re .
gurgitant volume and left ventricular afterload and improves
left ventricular function in aortic regurgitation (4-6), but
little information is available on the effect of long-term
therapy.
Controversies exist about the efficacy of long-term treat-
ment with hydralazine . A 6 month study (7) showed a
modest reduction in left ventricular afterload, no change in
left ventricular dilation and an increase in left ventricular
mass. These results do not support the use of hydratazine-
induced afterload reduction to diminish or retard the devel .
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twodhnenslaaal echocardlography . They also had a redutr
tlon in lent ventricular mean wall stress (360 t 27 versus
479 ± 36 kdyne/cmt, p < 0.001) and an Increase in ejection
fraction (72 t 8% versus 60 t 6%, p < 0.05) .
These data show that the long-term unloading action of
nifedipine is able to reverse left ventricular dilation and
hypertrophy and suggest that sack therapy has the
paten-
tad to
delay the need for valve replacement in asymptom-
ilk patients.
(! Am Cog Cardiof 1990;16.424-9)
opment of volume overload hypertrophy in chronic asymp-
tomatic aortic regurgitation
. More recently
. Greenberg et at .
(9) did show that 24 months of treatment with hydralaaine
reduced left ventricular end-diastolic volume and they sug-
gested that such therapy may have a beneficial effect on the
natural history of the disease . Unfortunately, left ventricular
mass was not measured in their study .
The present study was carried out to verify whether
long-term vasodilator therapy with nifedipine reduces left
ventricular overloading and, hence, the left ventricular end.
diastolic volume and mass in asymptomatic patients with
severe aortic regurgitation. This was a prospective, random-
ized, placebo-controlled, double-blind trial with left ventric-
ular measurements performed by quantitative two-
dimensional echocardiography .
Methods
Study patients. Seventy-two patients with chronic severe
aortic regurgitation were enrolled and randomized in this
study. The study protocol was approved by the Ethics
Committee of the University of Padua, and informed consent
was obtained in all cases . The severity of aortic regurgitation
(ranging from 3+ to 4+) was quantified by mapping the
regurgitant jet into the left ventricle by Doppler color flow
imaging in all patients. Aortic regurgitation was considered
to be present by Doppler color flow examination when an
0733-1097/9053.50
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abnormal diastolic flow originating from tile aortic valve was
visualized in the left ventricle. The severity of regurgitation
was graded using the jet height/left ventricular outflow tract
height ratio. The height of the regurghant jet was evaluated
at its origin immediately beneath the aortic valve in the
pamsterrial long-axis view. Values >45% indicated grade 3
and >65% grade 4 aortic regurgitation (9).
Twenty-eight patients underwent cardiac catheterization .
which confirmed grade 3 or 4 aortic regurgitation in each .
The main hemodynamic findings (mean values ± SD) were
left ventricular end-diastolic volume index 149 ± 16 mltm',
ejection fraction 58 t 10%, left ventricular mass 158 ± 20
glm' and left ventricular end-diastolic pressure 10
.
4 mm
Hg.
Selection of patients. Only asymptomatic patients were
included in this trial . Other exclusion criteria were atrial
fibrillation, diastolic blood pressure >90 mm Hg, history of
recent development or worsening of the aortic regurgitation
(within the preceding 6 months), history of coronary artery
disease, mixed aortic stenosis and regurgitation, evidence of
additional valvular or congenital heart disease by cardiac
catheterization or echocardiogmphic and Doppler evalua-
tion, or both, and previous vasodilator or diuretic drug or
inotropic therapy (previous therapy with cardioactive
drugs) . Admission to the study required a high quality
echocardiographic left ventricular study . Sixteen patients
>40 years of age underwent coronary arteriography; none
had significant stenosis (>50% diameter reduction) .
Protocol. The initial evaluation of all patients included a
complete history and physical examination, complete blood
count, blood chemistry screen and urinalysis, 12 lead elec-
trocardiogram (ECG), chest roentgenogram in the postero-
anterior and lateral projections and two-dimensional echo-
cardiographic study . On completion of baseline studies,
treatment was begun with either nifedipine (20 mg twice
daily) or a matching placebo preparation . Neither the study
physicians nor the patients were aware of which treatment
was given . The characteristics of the 72 patients who were
enrolled and randomized in the trial are listed in Table I .
Medication compliance was monitored during monthly re-
turn visits
. Echocardiographic evaluations were repeated at
6 and 12 months after randomization.
E
,
komrdiographic analysis Two-dimensional echocar-
diograms were recorded with a Hewlett-Packard phased
array ultrasonoscope and a 2 .5 or 3 .5 MHz transducer.
Measurements were performed at the end of the trial .
Echocardiographic examinations were coded and read by
two independent observers who did not know the patient's
identity, treatment or order of the studies. A discrepancy
?Itt ml for left ventricular volume and 2 :10 g for left
ventricular mass required analysis of the echocardiographic
tracing by a third observer . Agreement was achieved by
consensus . However, interobserver and intraobserver vari-
ability for left ventricular area (r = 0 .98 and r = 0.97,
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Table 1. Baseline Characteristics of 72 Randomized Patients With
Asymptomatic Annie Regurgitation
*Duration of
tunic regurgitation
(AR)
was established by historical
information from the patient or from physicians' records . Vases on mrcm
values -_ SD. DBP = diastole blood pressure ; EF - ejection faction ;
LVEDVI - left ventricular end-diastolic volume index ; LVESVI - leh
ventricular end-systege volane index; MWS = mean wall stress ; SBP =
systolic blood pressure .
respectively) and for left ventricular length (r = 0 .98 and r =
0
.96, respectively) was acceptable
.
Left ventricular enslocardial and epicardial echucardio-
grams in apical four chamber and parasternal short-axis
views in a minimum of three to five cardiac cycles were
digitized at end-diastole (R wave peak) and end-systole (time
of smallest cavity area) by two independent observers .
Left ventricular volumes were calculated by an ellipsoid
biplane area-length model (10); ejection fraction was derived
as: (EDV - ESV)IEDV, where EDV and ESV are left
ventricular end-diastolic and end-systolic volumes, respec-
tively . Left ventricular myocardial mass was calculated by
multiplying the myocardial volume by the specific weight of
cardiac muscle (1
.05 gimp
(It) .
Left
ventricular
mean wall stress (MWS) was measured
by combining peak arterial pressure measurements (PAP)
(cuff method) simultaneously with echocardiographic mea-
surements of left ventricular radius and posterior wall thick-
ness as follows: MWS = PAP X Rm(fhm, where Rm and
Thm are the averages of end-diastolic and end-systolic
values of the left ventricular radius (R) and wall thickness
(Th) . Radius and thickness measurements were performed
on M-mode tracings derived from two-dimensional visual-
ization of the left ventricle in the parasternal short-axis view .
Mean wall stress represents a good noninvasive indicator of
peak left ventricular and end-systolic wail stress as shown by
correlations with angiographic data (12).
Statistical tttraly3b
. Results are expressed as mean values
SD . Comparisons were assessed on the basis of the
two-way ANOVA analysis, with the Schefft method for
multiple comparison . A p value <0 .05 was considered to be
Flaceho
NilMpine p v"
No . 34 38
Age lyt) 38 5 12 34t 14 NS
Gender (oo .)
Men 20 34
Women 6 4
Duration of AR' (yr) 10 z 6
12 ± S
NS
LvEDVt twOw') 134- 14 136 ` 22 Ns
LVESVIimpw°l (0± 16 59 *_ t9 NS
EF171 56-5 58 •_ 6 NS
MWS (kdyne/cm') 484 _ 28
479!36
NS
Mass 4/m) 138 ! 18 142 ! 16 NS
Cardiotburaeie ma 0.53 x 406 0.52 ± 0.03
NS
Sap Im .Ha) I55±22 154! 19 NS
DBP (met Hg) 62 t 12 60 x 10 NS
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Table 2 . Side Effects in 72 Patients
ep < 0
.001 compared wirh placebo .
statistically significant . The ( test and chi-square method
were used for baseline comparisons of the groups for several
numeric and categoric characteristics, respectively .
Results
Baseline comparisons. Clinical characteristics and mea-
surements of left ventricular dimensions and function from
the baseline echocardiographic examinations in the groups
of randomized patients were similar (Table I) . A :; patients
had a left ventricular end-diastolic volume index greater than
the mean value ± 1 .5 SD for normal subjects in our labora-
tory. Ejection fraction was >50% in all patients. Normal
values ± SD and 95% confidence limits for these variables in
our laboratory are the following: left ventricular end-
diastolic volume index 64 t 6 ml/m 2 (range 54 to 74), left
ventricular end-systolic volume index 29 ± 3 mllm' (range 24
to 34) and ejection fraction 58 ± 3% (range 53% to 63%) . An
S 3 gallop was not detectable in any patients, but left ventric-
ular hypertrophy was detected on ECG examination in all
patients.
Patient follow-up. Seventy patients completed the 12
month follow-up evaluation. Two patients who had been
randomized to receive nifedipine were excluded from anal-
ysis (a 26 year old woman who stopped therapy after 4
months because of the appearance of leg edema and a 42
year old man who refused the monthly return visit after 3
months of therapy). All patients who had been randomized
to receive placebo were available for follow-up evaluation .
All study patients were asymptomatic and none required
surgery during the follow-up period .
Side effects . These were present in both placebo- and
nifedipine-treated patients (Table 2)
; 26% of the patients
randomized to receive placebo and 60% of the patients
randomized to receive nifedipine (p < 0.001) experienced at
least one new symptom during the first 3 months . At the 12
month return visit, side effects were present in 9% of the
placebo-treated group and 11% of the nifedipine-treate4
group (p = NS) .
JACC Vol. I6. No. 2
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Figure t
. Changes in left ventricular end-diastolic volume index
ILVEDVI over time in 72 study patients . Measurements obtained at
6 and i2 months were compared with baseline measurements from
the same patients. Left ventricular znd-diastolic volume index did
not change in the placebo-treated group, but decreased significantly
in patients treated with nifedipine .
Hemodynamk changes. Heart rate (baseline 72
t 12, 6
months 74 t 16 and 12 months 75 t 10 beats/min, respec-
tively), systolic blood pressure (155 t 22, 149 ± 20 and 153
± 21 mm Hg, respectively), diastolic blood pressure (62 ±
12, 64 ± 10 and 60 ± 10 mm Hg, respectively), cardiotho-
racic ratio (0.53 *- 0.06, 0.53 ± 0.05 and 0.53 ± 0.05) and
ECG pattern of left ventricular hypertrophy did not change
in the placebo group during follow-up. In the nifedipine-
treated group, heart rate did not change (74 ± 16, 75 t 10
and 78 t 10 beats/min, respectively ; p - NS), but blood
pressure was reduced significantly (154 ± 19, 138 t 16 and
134 ± 18 mm l-lg, respectively ; p < 0.01) for both the 6
month and the 12 month values compared with the baseline
value . Mild changes in diastolic blood pressure (65 ± 8 mm
Hg, P = NS) and cardiothoracic ratio (0.50 t 0.05, p = NS)
were observed. Electrocardiographic findings did not
change.
Analysis of Sell ventricular echocardlographlc measure-
meals.
Changes over time in left ventricular end-diastolic
volume index, ejection fraction, mean wall stress and mass
were assessed in the 70 randomized patients who concluded
the 12 month follow-up period, Left ventricular end-diastolic
%olume index (Fig, I) did not change significantly in the
placebo-treated group (138
t
20 versus 134 t 18 ml/m', p =
NS). Left ventricular end-diastolic volume index was re-
duced in the nifedipine-treated group and changes at 6 and 12
months were highly significant compared with both brseline
(110 t 19 versus 136 ± 22 mllm2 , n < 0 .01) and placebo-
treated group values (110 ± 19 versus 134 ± 18 ml/m 2, p <
0 .01). Left ventricular end-diastolic volume index was re-
<3 Months 12 Months
Placcho Nifedipine Placebo Nifedipine
No. 34 38 34 36
Headache 2 5 1 2
Flushing I I - -
Fatigue 2 4 2
Postural
hypotension
2 2 - -
Logedema - 3 - I
Taehycardia 2 8 -
I
Tool 9(26%) 23(60%1' 3 (990 4 (11%)
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Figure 2
. Changes in ejection fraction (EF) ove : time in the two
study groups
. Ejection fraction decreased slightly in the placebo-
treated group (opca circles) but increased in the nifedipine-treated
group (sogd cirdsa).
duced by 19% from the baseline value in patients who were
treated with nifedipine for 12 months.
A statistically significant reduction in ejection
fraction
(Fig. 2) was detectable in the placebo-treated patients (48 m
7% versus 39 ± 5%, p < 0.05) after 12 months of follow-up
evaluation. Patients receiving nifedipine showed an increase
in ejection fraction (72 ± 8% versus 60 ± 6%, p < 0.005).
Mean wall stress (Fig. 3) did not change in the placebo-
treated group (492 ± 25 versus 484 t 28 kdynelcm'- , p = NS)
but was significantly reduced in the nifedipine-treated group
compared with the baseline value (360 ± 27 versus 479 w 36
kdynelcm2, p < 0
.001) and the placebo-treated group values
(p < 0 .001)
.
Figure 3
. Changes in mean wall stress (MWS) over time for the two
study groups. Mean wall stress did not change from baseline values
in the placebo-treated group, but decreased in the nifedipine-treated
group .
6
months
12
months
LVM
160
g/m z
150
Figure 4. Changes in left ventricular mass (LVM) over time for the
two study grocys. Left ventricular mass did not change in patients
treated with placebo, but decreased significantly in the nifedipine-
treated patients.
Left ventricular mass (Fig. d) did not change in the
placebo-treated group (136 ± 20 versus 138 t 18 glm
2, p =
NS). In contrast, there was a significant reduction in left
ventricular mass in the nifedipine-treated group (115 m i9
versus 142 0 16 g/m2, p < 0 .01)
.
Discussion
In chronic severe aortic regurgitation, volume overload is
usually tolerated over a long period because of the develop-
ment of adaptational factors such as left ventricular dilation
and hypertrophy. Changes in the left ventricular loading
condition with increased left ventricular wall stress and
decreased myocardial efficiency (13) and the long-lasting
secondary hypertrophic process itself (14) can lead to myo-
cellular contractile dysfunction . However, the chronic vol-
ume-overloaded left ventricle can develop irreversible struc-
tural and functional damage even if the patient remains
asymptomatic
. Moreover, there is no reliable evidence that
early aortic valve replacement is indicated in asymptomatic
patients with normal left ventricular systolic function (1=
3
.15) . Therefore, it is mandatory to make an effort to define
the medical treatment for patients in the long asymptomatic
phase .
Previous studies on vasodilator therapy in aortic regurgi-
tation. Unloading agents may increase the myocardial effi-
ciency and limit the stimulus to hypertrophy by decreasing
left ventricular wall stress . Arterial vasodilators acutely
improve left ventricular hemodynamics in aortic regurgita-
tion by reducing peripheral vascular resistance and regur-
gitant flow
(4-6) .
The effects of long-term treatment with
SCOONAMIGLIO ET AL.
	
427
NIFEDIPINE IN AORTIC INSUFFICIENCY
429
	
SCOGNAMIGLIO ET AI..
NIFED(F1NE IN AORTIC INSUFFICIENCY
hydralazine have been evaluated in two prospective trials in
patients with aortic regurgitation . Kleaveland et al . (7)
concluded that 6 months of hydralazine therapy in maternal
tolerated doses neither altered the severity of regurgitation
nor reduced left ventricular enlargement and hypertrophy in
chic 'd severe aortic regurgitation, although systolic func-
tion may be
improved
. More recently, Greenberg et al. (8)
showed that 24 months of treatment with hydralazine re-
duced the volume overload in aortic regurgitation and sug-
gested that such therapy may have a beneficial effect on the
natural history of the disease. Unfortunately, this latter
study does not provide data regarding changes in left ven-
tricular
mass during hydralazine therapy. The disparity
between the two studies probably reflects some limitations
of the study by Kleaveland et al
. (7), namely, the small
sample size (six patients in the hydralazine-treated group),
limited follow-up period and use of M-mode echocardiog-
raphy for evaluating patients. M-mode echocardiography
does not gecurtely measure left ventricular volumes in
patients with aortic regurgitation (16,17) and is insensitive to
reductions in left ventricular volumes occurring after nitro-
glycerin administration (18). Two-dimensional echocardiog-
raphy is clearly superior in aortic regurgitation (17,18) and
has been used in our study to quantify changes in left
ventricular volume .
Long-term nifedipine unloading action . Nifedipine, a po-
tent calcium channel blocking vasodilator, may be an alter-
native approach to afteroad reduction in aortic regurgita-
tion
. Left ventricular dilation and hypertrophy develop in
response to chronic regurgitant flow and reflect the severity
and duration of aortic regurgitation (19) . Moreover, left
ventricular dilation and mass are important predictors of the
need for aortic valve replacement, and their high values can
limit the reversibility of left ventricular dysfunction after
surgery (1,2,14,20,21). Thus, it is probable that treatment
producing sustained reductions in left ventricular end-
diastolic volume and mass might retard the appearance of
irreversible structural myocardial lesions and delay aortic
valve replacement .
The results of this trial in asymptomatic patients with
aortic regurgitation and a normal ejection fraction clearly
demonstrate that long-term nifedipine unloading therapy
favorably affects left ventricular dimensions, hypertrophy
and function- 9oth left ventricular end-diastolic volume
index and mass were reduced in the patients treated with
nifedipine, and over time the changes were significantly
different from those in placebo-treated patients
. Regression
of left ventricularhypcrtrophy by nifedipine could be a result
of its complex pharmacologie activity, which includes sev-
eral components: 1) decreased afterload due to peripheral
vasodilation; 2)decrease in an abnormally increased calcium
uptake in the hypertrophic myocardium ; and 3) improve-
ment in coronary blood flow, which reverses the ischemic
stimulus to the development of myocardial hypertrophy.
IACC Val . 16, Na, 2
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This peculiar action could explain the important regression
in left ventricular hypertrophy produced by nifedipine and
the absence of significant changes with hydralazinc .
The sustained reduction in left ventricular wall stress,
detectable in nifedipine-treated patients may have been an
important factor for remodeling the left ventricle. Left
vcatticular wall stress is a Factor that strongly influences left
ventricular function in patients with aortic regurgitation
(20-24) and a sustained unloading action may be important
in delaying structural damage of myocardium . Moreover,
ejection fraction increased in the nifedipine-treated patients .
hut decreased in the placebo-treated patients .
Conclusions. Although larger and longer trials are re-
quirec' to demonstrate that nifedipine therapy can delay
aortic valve
replacement
our study suggests that early
unloading therapy has the potential to favorably influence
the natural history of asymptomatic patients with chronic
severe aortic regurgitation. Left ventricular dilation and a
high level of left ventricular stress seem to be reasonable
indicators for vasodilator therapy, despite a normal left
ventricular ejection fraction .
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